Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CLBS14 · CLBS-119, CLBS-12

Cell therapy · developed by Lisata Therapeutics

Phase 2 Most advanced trial (none active)
LSTA Developer
2 Registered trials

What is CLBS14?

CLBS14 is an autologous cell therapy made of CD34+ cells mobilized from the bone marrow with G-CSF, selected from apheresis product and delivered as intramyocardial injections into areas of myocardial ischemia. It is studied in myocardial ischemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CLBS-119, CLBS-12
Drug type
Cell therapy
Therapy area
Cardiovascular
Developer
Lisata Therapeutics, Inc. (LSTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
MMJ7T8VNQ7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01508910 Phase 3 Chronic Myocardial Ischemia Completed LSTA
NCT00300053 Phase 2 Myocardial Ischemia Completed LSTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myocardial Ischemia

More from Lisata Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.

Follow LSTA, the company behind CLBS14

See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LSTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.